Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SPHINGOLIPID METABOLISM: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet. View on Wiki →
| Name | SPHINGOLIPID METABOLISM |
| Key Genes/Proteins | IL-10, AMYLOID, APP |
| Related Diseases | ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, DEMENTIA |
| Linked Hypotheses | 1 hypotheses |
Knowledge base pages for this entity
graph TD
SPHINGOLIPID_METABOLISM["SPHINGOLIPID METABOLISM"]
SPHINGOLIPID_METABOLISM -->|"contributes to"| Inflammation["Inflammation"]
SPHINGOLIPID_METABOLISM -->|"involved_in"| Alzheimer_s_Disease["Alzheimer's Disease"]
SPHINGOLIPID_METABOLISM -->|"contributes to"| Endoplasmic_Reticulum_Stress["Endoplasmic Reticulum Stress"]
SPHINGOLIPID_METABOLISM -->|"involved_in"| Parkinson_s_Disease["Parkinson's Disease"]
SPHINGOLIPID_METABOLISM -->|"inhibits"| STEM_CELLS["STEM CELLS"]
EMP1["EMP1"] -->|"inhibits"| SPHINGOLIPID_METABOLISM
IL_10["IL-10"] -->|"inhibits"| SPHINGOLIPID_METABOLISM
IL10["IL10"] -->|"inhibits"| SPHINGOLIPID_METABOLISM
GLUCOCEREBROSIDASE["GLUCOCEREBROSIDASE"] -->|"catalyzes"| SPHINGOLIPID_METABOLISM
ASMASE["ASMASE"] -->|"involved_in"| SPHINGOLIPID_METABOLISM| Target | Relation | Type | Str |
|---|---|---|---|
| STEM CELLS | inhibits | cell_type | 0.35 |
| Source | Relation | Type | Str |
|---|---|---|---|
| IL10 | inhibits | entity | 0.90 |
| EMP1 | inhibits | entity | 0.90 |
| INFLAMMATION | metabolizes | process | 0.35 |
| IL-10 | metabolizes | gene | 0.35 |
| ENDOPLASMIC RETICULUM STRESS | inhibits | process | 0.35 |
| HIPPOCAMPUS | metabolizes | brain_region | 0.35 |
| AMYLOID | metabolizes | protein | 0.35 |
| ALZHEIMER'S DISEASE | implicated_in | disease | 0.35 |
| MICROGLIA | implicated_in | cell_type | 0.35 |
| ALZHEIMER'S DISEASE | metabolizes | disease | 0.35 |
| AMYLOID | therapeutic_target | protein | 0.35 |
| APP | therapeutic_target | gene | 0.35 |
| PARKINSON'S DISEASE | metabolizes | disease | 0.35 |
| DEMENTIA | metabolizes | disease | 0.35 |
| PULMONARY FIBROSIS | activates | disease | 0.35 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Sphingolipid Metabolism Reprogramming | 0.443 | neurodegeneration | 4R-tau strain-specific spreading pattern |
Scientific analyses that reference this entity
No analyses mention this entity
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| EMP1 safeguards hematopoietic stem cells by suppressing sphingolipid metabolism [PMID:40624017] | Li L, Lei Y, Li Y, Xie Y, Hui P, Zang X, | Nat Commun | 2025 | 1 |
| IL-10 constrains sphingolipid metabolism to limit inflammation. [PMID:38383790] | York AG, Skadow MH, Oh J, Qu R, Zhou QD, | Nature | 2024 | 1 |
| PAQR4 regulates adipocyte function and systemic metabolic health by mediating ce [PMID:38961186] | Zhu Q, Chen S, Funcke JB, Straub LG, Lin | Nat Metab | 2024 | 1 |
| Sirtuin 1 mediated ceramide metabolism regulates intestinal mechanical barrier f [PMID:41856194] | Ma X, Liu Q, Mai K, Zhang Y | Int J Biol Macromol | 2026 | 0 |
| Metabolic abnormalities and reprogramming in cats with naturally occurring hyper [PMID:39499136] | ["Li Q", "Homilius M", "Achilles E", "Ma | ESC heart failure | 2025 | 0 |
| Reduced circulating sphingolipids and CERS2 activity are linked to T2D risk and [PMID:39792658] | Khan SR, Ye WW, Van JAD, Singh I, Rabiee | Science advances | 2025 | 0 |
| Very long-chain fatty acids drive 1-deoxySphingolipid toxicity. [PMID:41298489] | ["Majcher A", "Karsai G", "Yusifov E", " | Nature communications | 2025 | 0 |
| A multi-omics approach identifies the key role of disorders of sphingolipid meta [PMID:39638825] | ["Qu Y", "Ma D", "Wu T", "Wang H", "Tian | Scientific reports | 2024 | 0 |
| Disruption of adipocyte HIF-1α improves atherosclerosis through the inhibition o [PMID:35847503] | Wang P, Zeng G, Yan Y, Zhang SY, Dong Y, | Acta pharmaceutica Sinica. B | 2022 | 0 |
| Fumonisin B [PMID:35777715] | ["Li M", "Liu S", "Tan L", "Luo Y", "Gao | Food and chemical toxicology : | 2022 | 0 |
| Omega-3 polyunsaturated fatty acids reverse the impact of western diets on regul [PMID:35985403] | ["Camacho-Mu\u00f1oz D", "Niven J", "Kuc | Biochemical pharmacology | 2022 | 0 |
| Metabolic Reprogramming-A New Era How to Prevent and Treat Graft Versus Host Dis [PMID:33343357] | ["Kumari R", "Palaniyandi S", "Hildebran | Frontiers in pharmacology | 2020 | 0 |
| Evolution to the rescue: using comparative genomics to understand long non-codin [PMID:27573374] | ["Ulitsky I"] | Nature reviews. Genetics | 2016 | 0 |
| New insights into the organ-specific adverse effects of fumonisin B1: comparison [PMID:25155190] | ["Loiseau N", "Polizzi A", "Dupuy A", "T | Archives of toxicology | 2015 | 0 |
| Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Cl [PMID:25452455] | ["Stoffel E", "Mangu P", "Gruber S", "Ha | Journal of clinical oncology : | 2015 | 0 |
| Ceramide synthase 4 deficiency in mice causes lipid alterations in sebum and res [PMID:24738593] | ["Ebel P", "Imgrund S", "Vom Dorp K", "H | The Biochemical journal | 2014 | 0 |
| Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determine [PMID:23209295] | ["Zhu Y", "Massen S", "Terenzio M", "Lan | The Journal of biological chem | 2013 | 0 |